Contact us Career

Market Updates

Pharmaceutical Drugs Going off Patent in 2018

June, 2018

Patent expiry is one of the major factor affecting the company revenue. Often when the generic competitor of a blockbuster drugs enters the market, the sales of the blockbuster drugs has decreased significantly. For instance, the patent expiry of Pfizer’s Lipitor has resulted in about 90% decrease in the annual sales revenue of the drug. In 2016, Astra Zeneca lost patents for two major drugs, Cestor and Seroquel XR which accounted for a combined revenue of $7.34 billion annually. In 2017, Merck lost the patents for four drugs (Invanz, Vytorin, Cancidas, and Cubicin) that was estimated to value around $3.4 billion, which is 10% of their 2015 revenue.

Here are a few of the key drugs going off-patent in 2018.

AcanyaValeant Pharmaceuticals International, IncSkin (topical) to treat acne vulgaris
AdcircaUnited Therapeutics Corporationpulmonary arterial hypertension
AdavirGlaxoSmithKlineAsthma and COPD
AmpyraAcorda TherapeuticsMultiple Sclerosis
AtriplaGilead Sciences, IncHIV
CialisEli LillyErectile dysfunction
Epogen/ProcritAmgen and Johnson & JohnsonAnemia
FentoraCephalon, IncManagement of breakthrough pain in cancer patients
FinaceaBayer HealthCare Pharmaceuticals.Hyperpigmentation
FortestaEndo PharmaceuticalsHypogonadism
LevitraBayer HealthCare Pharmaceuticals.Erectile dysfunction
LetairisGilead Sciences, IncPulmonary arterial hypertension
Lotronexsevere irritable bowel syndrome (IBS)Sebela Pharmaceutical
LyricaPfizerNerve and muscle pain
MakenaAMAG Pharmaceuticals, IncFemale Hormone Related Cancer
Namenda XRAllerganDementia
PradaxaBoehringer Ingelheim Pharmaceuticals, Inc.blood thinner
PromactaNovartisTo treat low blood platelet counts due to chronic immune (idiopathic) thrombocytopenia (ITP)
RemodulinUnited TherapeuticsPulmonary arterial hypertension
RevlimidAmgenWhite blood cell booster
RestasisAllerganDry Eyes
RituxanRocheBlood cancers, rheumatoid arthritis
Sensipar TabletAmgenCalcium Reducer
SpirivaBoehringer Ingelheim Pharmaceuticals, Inc.Chronic Obstructive Pulmonary Disease (COPD)
StaxynGlaxoSmithKlineErectile dysfunction
SymbicortAstra ZenecaAsthma
TekturnaNoden Pharma USA IncBlood Pressure
TikosynPfizerIrregular Heartbeat
VesicareAstellas PharmaOveractive Bladder
XolairRoche/NovartisAllergic asthma and chronic idiopathic urticaria
ZytigaJohnson & JohnsonProstate cancer


Company wise analysis

company wise analyse

- Rikitha
Healthcare Market Research Analyst
Infoholic Research